Alex Spira, MD PhD FACP VCS Co-Author Virginia Cancer Specialists - JAMA Network - Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas Clinical Trial

Question  In patients with advanced soft tissue sarcoma (STS), does the addition of olaratumab to doxorubicin improve overall survival?

Findings  In this randomized clinical trial of 509 adults with advanced STS, there was no significant difference in overall survival between patients who received doxorubicin plus olaratumab and patients who received doxorubicin plus placebo in the total STS and leiomyosarcoma populations (total STS: hazard ratio, 1.05; median, 20.4 vs 19.7 months; leiomyosarcoma: hazard ratio, 0.95; median, 21.6 vs 21.9 months).

Meaning  There was no significant difference in overall survival with the addition of olaratumab to doxorubicin in patients with advanced STS.